EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Transfer of Cardiac Mitochondria Improves the Therapeutic Efficacy of Mesenchymal Stem Cells in a Preclinical Model of Ischemic Heart Disease

Marie-Luce Vignais iD, Jennyfer Levoux, Pierre Sicard iD, Khattar Khattar, Catherine Lozza iD, Marianne Gervais, Safia Mezhoud, Jean Nakhle, Frederic Relaix iD, Onnik Agbulut, Jeremy Fauconnier iD, Anne-Marie Rodriguez iD

Cells · 2023

DOI: 10.3390/cells12040582 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, 2023. Verfasst von Marie-Luce Vignais und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institut de Génomique Fonctionnelle, University Montpellier, CNRS, INSERM, 34094 Montpellier, France. Hauptthemen laut MEDLINE: Myocardial Ischemia, Myocardial Infarction, Mesenchymal Stem Cells. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondation de l’Avenir, Agence Nationale pour la Recherche, Université Paris Est Créteil.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The use of mesenchymal stem cells (MSCs) appears to be a promising therapeutic approach for cardiac repair after myocardial infarction. However, clinical trials have revealed the need to improve their therapeutic efficacy. Recent evidence demonstrated that mitochondria undergo spontaneous transfer from damaged cells to MSCs, resulting in the activation of the cytoprotective and pro-angiogenic functions of recipient MSCs. Based on these observations, we investigated whether the preconditioning of MSCs with mitochondria could optimize their therapeutic potential for ischemic heart disease.

Methods

Human MSCs were exposed to mitochondria isolated from human fetal cardiomyocytes. After 24 h, the effects of mitochondria preconditioning on the MSCs’ function were analyzed both in vitro and in vivo.

Results

We found that cardiac mitochondria-preconditioning improved the proliferation and repair properties of MSCs in vitro. Mechanistically, cardiac mitochondria mediate their stimulatory effects through the production of reactive oxygen species, which trigger their own degradation in recipient MSCs. These effects were further confirmed in vivo, as the mitochondria preconditioning of MSCs potentiated their therapeutic efficacy on cardiac function following their engraftment into infarcted mouse hearts.

Conclusions

The preconditioning of MSCs with the artificial transfer of cardiac mitochondria appears to be promising strategy to improve the efficacy of MSC-based cell therapy in ischemic heart disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myocardial IschemiaMyocardial InfarctionMesenchymal Stem CellsMiceAnimalsHumansMyocytes, CardiacMitochondria, Heart

Stichwörter der Autor:innen

cell therapymesenchymal stem cellsmetabolismmitochondria transferpost-ischemic heart failure

Autor:innen und Institutionen

  • Institut de Génomique Fonctionnelle, University Montpellier, CNRS, INSERM, 34094 Montpellier, France.
  • Université Paris-Est Créteil, INSERM, IMRB, 94010 Créteil, France.
  • Sorbonne Université, Institut de Biologie Paris-Seine (IBPS), CNRS UMR 8256, INSERM U1164, Biological Adaptation and Ageing, 75005 Paris, France.
  • PhyMedExp, Inserm, CNRS, University of Montpellier, 34295 Montpellier, France.
  • École Nationale Vétérinaire d'Alfort, IMRB, 94700 Maisons-Alfort, France.
  • APHP, Hôpitaux Universitaires Henri Mondor & Centre de Référence des Maladies Neuromusculaires GNMH, 94000 Créteil, France.

ORCID-Profile: Marie-Luce Vignais, Pierre Sicard, Catherine Lozza, Frederic Relaix, Jeremy Fauconnier, Anne-Marie Rodriguez

Förderung

  • Fondation de l’Avenir
  • Agence Nationale pour la Recherche
  • Université Paris Est Créteil
  • Fondation pour la Recherche Médicale
  • Region Occitanie (GliMit)

Zitieren

APA

Vignais, M. L., Levoux, J., Sicard, P., Khattar, K., Lozza, C., Gervais, M., Mezhoud, S., Nakhle, J., Relaix, F., Agbulut, O., Fauconnier, J., & Rodriguez, A. M. (2023). Transfer of Cardiac Mitochondria Improves the Therapeutic Efficacy of Mesenchymal Stem Cells in a Preclinical Model of Ischemic Heart Disease. Cells. https://doi.org/10.3390/cells12040582

Vancouver

Vignais ML, Levoux J, Sicard P, Khattar K, Lozza C, Gervais M, et al. Transfer of Cardiac Mitochondria Improves the Therapeutic Efficacy of Mesenchymal Stem Cells in a Preclinical Model of Ischemic Heart Disease. Cells. 2023. doi:10.3390/cells12040582

BibTeX
@article{Vignais2023,
  author = {Vignais, Marie-Luce and Levoux, Jennyfer and Sicard, Pierre and Khattar, Khattar and Lozza, Catherine and Gervais, Marianne and Mezhoud, Safia and Nakhle, Jean and Relaix, Frederic and Agbulut, Onnik and Fauconnier, Jeremy and Rodriguez, Anne-Marie},
  title = {Transfer of Cardiac Mitochondria Improves the Therapeutic Efficacy of Mesenchymal Stem Cells in a Preclinical Model of Ischemic Heart Disease},
  journal = {Cells},
  year = {2023},
  doi = {10.3390/cells12040582}
}
Kostenlos starten →